Diabetes devices market to be driven by rising CASES of diabetes worldwide due to the growing aging population, advancement in diabetes technology and increased awareness among people

Diabetes Devices Market, Global Diabetes Devices Market, Diabetes Devices Industry, Diabetes Devices Market Size, Diabetes Devices Market Share, Diabetes Devices Market Research, Diabetes Devices Market Trends

Market Research Future (MRFR) has published a cooked research report on the “Global Diabetes devices Market” that contains information from 2018 to 2032. The diabetes devices market is estimated to register a CAGR of 7.80% during the forecast period of 2023 to 2032.

Diabetes Devices Market Highlights

The global diabetes devices market is accounted to register a CAGR of 7.80% during the forecast period and is estimated to reach USD 55.6 billion by 2032.

The number of green hydrogen projects is growing as more nations focus their investments on the development of a hydrogen-based economy. The potential for longer-term reuse of carbon-free hydrogen in the production of diabetes devices is anticipated to grow as a result of investments in hydrogen infrastructure. Additionally, the move towards zero-carbon through decarbonization is anticipated to spur the use of diabetes devices, which is anticipated to promote the growth of the global diabetes devices market.

Key Players

MRFR recognizes the following companies as the key players in the global diabetes devices market— Abbott Laboratories; F.Hoffmann-La-Ltd.; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; and Arkray, Inc.

Segment Analysis

The global diabetes devices market has been segmented based on type, distribution channel and end use.

On the basis of type, the market is segmented into Blood Glucose Monitoring Devices and Insulin Delivery Devices. The blood glucose monitoring devices segment was attributed to holding the largest market share in 2022, because it has a broad application and the growing awareness among individuals and advancements in technology.

Based on distribution channel, the global diabetes devices market has been segmented into Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centres, Online Pharmacies and Others. The hospital pharmacies segment was expected to hold the largest market share in 2022, as it offers specialized devices.

Based on end use, the global diabetes devices market has been segmented into Hospitals, Homecare and Diagnostic Centres. The hospitals segment was expected to hold the largest market share in 2022, due to the rising number of hospital admissions.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Diabetes Devices Market Research Report

Regional Analysis

The global diabetes devices market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe diabetes devices market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The diabetes devices market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World diabetes devices market comprises of Middle East, Africa, and Latin America.

The largest market share for diabetes devices was maintained by the North American regional sector. This increase is attributed to the highest prevalence of diabetes in the world, driving the demand for diabetes devices. The region boasts a well-developed and advanced healthcare infrastructure, with a strong network of healthcare facilities. Further, the region has a higher level of access to healthcare services and also hub for technological innovation and research and development. Moreover, the region has a high level of awareness and health literacy among the population in North American region.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for diabetes devices is driven by rising cases of diabetes, advanced healthcare infrastructure, technological advancements in healthcare. The region is home to several prominent diabetes research centers and institutions and has an aging population, and diabetes is more common among older adults.

Additionally, Asia Pacific is home to a significant and rapidly expanding population, and diabetes prevalence rates have been on rise due to lifestyle changes, urbanization and dietary habits. There has been a growing emphasis on diabetes prevention, early diagnosis and effective management, leading to increased demand for a wide range of diabetes devices. The adoption of advanced technologies, government initiatives and healthcare policies in several APAC countries is boosting the market growth in this region.

Furthermore, the rest of the world's diabetes devices market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising prevalence of diabetes and presence of developed healthcare infrastructure. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global diabetes devices market is expected to reach USD 55.6 billion by 2032, at a CAGR of 7.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the increasing prevalence of diabetes worldwide and introduction of new and technologically advanced products.


• Based on type, the blood glucose monitoring devices segment was attributed to holding the largest market in 2022, with an approximate market share of 50-70%.


• Abbott Laboratories; F.Hoffmann-La-Ltd.; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; and Arkray, Inc.